Fearon et al., 2005 - Google Patents

Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss

Fearon et al., 2005

View PDF
Document ID
11063392929687849659
Author
Fearon U
Mullan R
Poole R
Markham T
FitzGerald O
Bresnihan B
Veale D
Publication year
Publication venue
Arthritis Research & Therapy

External Links

Snippet

Methods Microvascular endothelial cells (EC), primary RA synovial fibroblasts (SFC), synovial explant culture and RASFC/normal cartilage co-cultures were stimulated with OSM (20 ng/ml)±IL-1 (5 ng/ml). Cell proliferation, cell adhesion molecules expression, tubule …
Continue reading at link.springer.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis

Similar Documents

Publication Publication Date Title
Goldring The effects of inflammatory arthritis on bone remodeling
Davis et al. Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes
Lundberg et al. Expression of IL-18 in muscle tissue of patients with treatment-resistant idiopathic inflammatory myopathies
Tolboom et al. The invasiveness of fibroblast-like synoviocytes is of relevance for the rate of joint destruction in patients with rheumatoid arthritis and is a patient characteristic
Kliwinski et al. Prophylactic administration of abatacept (CTLA4-Ig; BMS-188667) prevents disease induction and bone destruction in a rat model of collagen-induced arthritis
Baraliakos et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
Rao et al. The transcription T-bet is required for optimal proinflammatory trafficking of CD4+ T cells
Zandman-Goddard et al. Elevated titers of anti-ribosomal-P antibodies in systemic lupus erythematosus
Auger et al. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrin
Zhang et al. Sustained downregulation of the TCRζ chain defines a transition from antigen mode to inflammation mode during terminal T-cell differentiation
Panayi et al. Chaperonins and the regulation of immunity
Zwerina et al. Heme oxygenase 1 regulates osteoclastogenesis
Mueller et al. Regulation of myeloid cell function and MHC class II expression by tumor necrosis factor
van Bilsen et al. Functional regulatory immune responses against human cartilage glycoprotein-39 in health versus proinflammatory responses in rheumatoid arthritis
van Gaalen et al. Altered composition of CD97 splice variants in rheumatoid synovial tissue
Kinloch et al. Citrullinated α enolase, a novel citrullinated autoantigen in rheumatoid arthritis, upregulated by chronic inflammation
Kinne et al. Cytokine expression was assessed during antigen-induced arthritis in the synovial membrane, inguinal lymph node, and spleen using competitive RT-PCR and sandwich ELISA
Al-Shehhi et al. Does the burden of inflammation determined prospectively in patients with early inflammatory arthritis determine the progression of atherosclerosis?
Fearon et al. Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss
Koenders et al. Neutralizing IL-17 during re-activation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and IL-1
Glocker et al. Molecular signatures of rheumatoid arthritis characterized by transcriptome and proteome analysis
Smith Stem cells now and in the future in medicine
Baraliakos et al. Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis
Undeutsch et al. Type 1 regulatory T cells in treatment of murine lupus
Baraliakos et al. Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years